This was the case with the EGFR TKIs, where the biomarker of interest was initially thought to be EGFR protein expression (30) but pre-specified subgroup analysis confirmed a greater benefit for this therapy in patients with the presence of EGFR mutation in the tumor (12, 31–33). This evidence concerns the gene EGFR and neoplasm.